Compare Invesco Ltd. (IVZ) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Invesco Ltd. trades at $27.87 (market cap $12.77B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Invesco Ltd. is far larger — about 13.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Invesco Ltd. pays a 2.97% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Ltd. for 77 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IVZ | MRVI | |
|---|---|---|
Market Cap | $12.77B | $972.90M |
Volume | 2,758,656 | 4,325,710 |
Sector | Financials | Health |
52-Week High | $33.31 | $9.00 |
52-Week Low | $22.44 | $2.83 |
Typical Hold Time | 77 Days | 0 Days |
Enterprise Value | $22.93B | $1.08B |
Dividend Yield | 2.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $27.93, down 4.55% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $281.70 million in 2025 despite revenue growth to $6.38 billion, with a negative net income margin of -0.93%. Recent news highlights product expansions, including the launch of the Invesco Nasdaq International Innovators 100 ETF, and a dividend of $0.22 per share scheduled for September 2026.
The outlook is cautious; analyst consensus is a buy with a $33.17 price target, but profitability challenges and bearish technicals pose risks. Positive cash flow and AUM growth offer potential, yet investors must weigh weak margins against strategic initiatives in a competitive ETF landscape.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
